Imatinib use for gastrointestinal stromal tumors among older patients in Japan and Taiwan
Abstract Tyrosine kinase inhibitors (TKIs) improve the prognosis of patients with gastrointestinal stromal tumors (GISTs). We conducted a retrospective cohort study using cancer registries linked with health utilization data in Japan and Taiwan to assess TKI usage in older and non-older patients. Pa...
Main Authors: | Yuichi Ichinose, Yi-Hsin Yang, Hui-Jen Tsai, Ru-Yu Huang, Takahiro Higashi, Toshirou Nishida, Li-Tzong Chen |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-12-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-022-27092-z |
Similar Items
-
Recent Progress and Challenges in the Diagnosis and Treatment of Gastrointestinal Stromal Tumors
by: Toshirou Nishida, et al.
Published: (2021-06-01) -
Heterogeneity of Metabolic Vulnerability in Imatinib-Resistant Gastrointestinal Stromal Tumor
by: Wen-Kuan Huang, et al.
Published: (2020-05-01) -
MDCT appearance of gastrointestinal stromal tumors after therapy with imatinib mesylate.
by: Warakaulle, DR, et al.
Published: (2006) -
Imatinib enchances the sensitivity of gastrointestinal stromal tumors to topoisomerase II inhibitors
by: S. V. Boichuk, et al.
Published: (2015-06-01) -
Advances in the research of the mechanism of secondary resistance to imatinib in gastrointestinal stromal tumors
by: Xiangchen Hu, et al.
Published: (2022-09-01)